U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Amikacin – Injection Products
  1. Development Resources

Amikacin – Injection Products

Recognized Interpretive Criteria
FDA Identified Interpretive Criteria

 

Minimum Inhibitory Concentrations
(mcg/mL)

Disk Diffusion
(zone diameter in mm)

Pathogen

S

I

R

S

I

R

Enterobacterales

≤ 16

32

≥ 64

≥ 17

15 – 16

≤ 14

Pseudomonas aeruginosa

≤ 16

32

≥ 64

≥ 17

15 – 16

≤ 14

Acinetobacter spp.

M100 standard is recognized

Other non-Enterobacterales

M100 standard is recognized

-

-

-

Staphylococcus aureus

≤ 16

32

≥ 64

≥ 17

15-16

≤ 14

S = Susceptible; I = Intermediate; R = Resistant

Back to Top